-
2026-10-10
GenSci's Oncology Innovation: NDA Approval Secured for Prostate CancerLearn More
-
2026-10-09
GenSci's Two Innovations Received IND Clearance from NMPALearn More
-
2026-09-03
GenSci Showcases Innovation at CPHI Korea 2026Learn More
-
2026-08-13
GenSci's Ophthalmology Pipeline: IND Approval Secured for Three IndicationsLearn More
-
2026-07-31
GenSci144, a Novel SLC6A19 Inhibitor, Receives IND Approval from NMPALearn More
-
2025-10-24
GenSci Announces Positive Phase II Results for GS1-144 Tablets in Chinese Postmenopausal Women with Moderate-to-Severe VMSLearn More
-
2025-10-13
GenSci Advances Women's Health with the Approval of Two Key ProductsLearn More
-
2025-10-09
From Long-acting Growth Hormone to Medical Devices: GenPEG Advances its High-purity ExpertiseLearn More
-
2025-09-18
GenSci Partners with Allergy Immunotherapy Leader ALK to Bring Innovative AIT Solutions for Chinese PatientsLearn More
-
2025-07-14
First Prescription for Firsekibart Issued in China for GALearn More
-
2025-07-04
Firsekibart Approved with 87% Reduction in Gout Recurrence Over 6 MonthsLearn More